Results 81 to 90 of about 766 (122)

Determination of Carbocysteine from Human Plasma

Journal of Pharmaceutical Sciences, 1978
A fast and accurate GLC procedure for determining carbocysteine, using a sulfur photometric detector, is described. Interferences from nonsulfur constituents are eliminated. The method is linear from 2 to 15 micrograms. Results from the application of this method to a bioavailability study in humans are given.
W R, Maynard, R B, Bruce, G G, Fox
exaly   +3 more sources

Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases

Expert Opinion on Pharmacotherapy, 2009
Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders characterized by excessive, viscous mucus, including chronic obstructive airways disease (COPD).The intriguing antioxidant and anti-inflammatory properties of ...
Giovanni Mantovani, Clélia Madeddu, Antonio Maccio   +2 more
exaly   +4 more sources

Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness

Pharmacological Research, 1995
We investigated the possible effects of the mucoactive drug Carbocysteine lysine salt monohydrate (CLS.H2O) on experimentally-induced airway inflammation and hyperresponsiveness. CLS.H2O given by the oral route (300 mg kg(-1)) significantly reduced neutrophil infiltration into the airway lumen induced by intratracheal injection of IL-1 beta in rats. In
L Daffonchio, G Melillo, C Omini
exaly   +3 more sources

Relative bioavailability of carbocysteine from three dosage forms investigated in healthy volunteers

Biopharmaceutics and Drug Disposition, 1988
AbstractThe aim of the present study was to evaluate the bioavailability of a new tablet formulation of carbocysteine relative against two other oral carbocysteine containing dosage forms, viz. a syrup and capsules. Plasma levels and urine concentrations of carbocysteine were monitored, following oral administration of all three dosage forms to healthy
exaly   +3 more sources

Topical carbocysteine: A new option for the treatment of ichthyosis

Pediatric Dermatology, 2018
AbstractN‐acetylcysteine in combination with urea is effective for the treatment of congenital ichthyosis. Although it is well tolerated, its foul smell may compromise treatment adherence. Carbocysteine is a similar molecule without that bad odor. Thus, we have tried a new formula with carbocysteine for the treatment of 4 patients with ichthyosis, with
Ana Batalla, Carmen Dávila‐Pousa, Carlos Feal, Ángeles Flórez   +3 more
openaire   +2 more sources

Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification

European Journal of Clinical Pharmacology, 1991
A quantitative study has been made of the metabolism of S-carboxymethyl-L-cysteine (CMC) and its sulphoxides in volunteers by HPLC. Precolumn derivatization was applied prior to gradient reversed phase HPLC separation and fluorescence detection. For CMC and its metabolites containing a primary amino group the reagent 9-fluorenylmethylchloroformate was ...
J, Brockmöller, B, Staffeldt, I, Roots
openaire   +2 more sources

Investigational Drug Information; Carbocysteine

Drug Intelligence & Clinical Pharmacy, 1988
Carbocysteine is prescribed for conditions characterized by the accumulation of excessive mucus. Although often described as a mucolytic, its function is probably that of mucoregulation, which results in physical changes in accumulated secretions that are favorable in terms of clearance.
openaire   +1 more source

Spectroscopic, structural and drug docking studies of carbocysteine

Journal of Molecular Structure, 2017
Abstract Carbocysteine or carbocisteine having the empirical formula C 5 H 9 NO 4 S,is one of the most therapeutically prescribed expectorant, sold under the brand name viz., Mucodyne (UK and India), Rhinathiol and Mucolite. In pediatric respiratory pathology, it can relieve the symptoms of obstructive pulmonary disease (COPD) and bronchiectasis ...
M. Manivannan, K. Rajeshwaran, R. Govindhan, B. Karthikeyan   +3 more
openaire   +1 more source

[Carbocysteine in catarrhal ORL diseases].

Revue de laryngologie - otologie - rhinologie, 1991
By stimulating an enzyme, the sialyltransferase, Carbocisteine has a privileged place in mucomodifying therapeutics. It allows the substitution of pathologic secretions, congesting and aggressive, by physiologic restructured mucus. Tested with success in the E.N.T.
J P, Bébéar, V, Calas, B, Lablache Combier   +2 more
openaire   +1 more source

Antioxidant activity of carbocysteine lysine salt monohydrate.

Panminerva medica, 2001
Reactive oxygen radicals are involved in many respiratory diseases, including chronic obstructive pulmonary disease (COPD). Carbocysteine lysine salt monohydrate (CLS) is a mucoactive drug effective in the treatment of bronchopulmonary diseases characterized by mucus alterations, including COPD. In the present study, the antioxidant activity of CLS was
PINAMONTI, Silvano, VENTUROLI L, LEIS, Marilena, CHICCA, Milvia, BARBIERI A, SOSTERO, Silvana, RAVENNA F, DAFFONCHIO L, NOVELLINI R, CIACCIA, Adalberto   +9 more
openaire   +4 more sources